Yes

Contraceptive; Progestin

Endometrial carcinoma or renal carcinoma as well as secondary amenorrhea or abnormal uterine bleeding due to hormonal imbalance; prevention of pregnancy

X

Pregnancy, thrombophlebitis; hypersensitivity to medroxyprogesterone or any component; cerebral apoplexy, undiagnosed vaginal bleeding, liver dysfunction

Use with caution in patients with depression, diabetes, epilepsy, asthma, migraines, renal or cardiac dysfunction; pretreatment exams should include PAP smear, physical exam of breasts and pelvic areas. May increase serum cholesterol, LDL, decrease HDL and triglycerides; use of any progestin during the first 4 months of pregnancy is not recommended; monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine, and signs and symptoms of thromboembolic disorders.

>10%:

Cardiovascular: Edema

Endocrine & metabolic: Breakthrough bleeding, spotting, changes in menstrual flow, amenorrhea

Gastrointestinal: Anorexia

Local: Pain at injection site

Neuromuscular & skeletal: Weakness

1% to 10%:

Cardiovascular: Embolism, central thrombosis

Central nervous system: Mental depression, fever, insomnia

Dermatologic: Melasma or chloasma, allergic rash with or without pruritus

Endocrine & metabolic: Changes in cervical erosion and secretions, increased breast tenderness

Gastrointestinal: Weight gain or loss

Hepatic: Cholestatic jaundice

Local: Thrombophlebitis

Toxicity is unlikely following single exposures of excessive doses

Supportive treatment is adequate in most cases

Decreased effect: Aminoglutethimide may decrease effects by increasing hepatic metabolism

Inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation, stimulates growth of mammary tissue

Absorption: I.M.: Slow

Bioavailability: 0.6% to 10%

Protein binding: 90%

Metabolism: Oral: In the liver

Half-life: 30 days

Elimination: Oral: In urine and feces

Adolescents and Adults: Oral:

Amenorrhea: 5-10 mg/day for 5-10 days or 2.5 mg/day

Abnormal uterine bleeding: 5-10 mg for 5-10 days starting on day 16 or 21 of cycle

Accompanying cyclic estrogen therapy, postmenopausal: 2.5-10 mg the last 10-13 days of estrogen dosing each month

Adults: I.M.:

Endometrial or renal carcinoma: 400-1000 mg/week

Contraception: 150 mg every 3 months

Dosing adjustment in hepatic impairment: Dose needs to be lowered in patients with alcoholic cirrhosis

Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine, and signs and symptoms of thromboembolic disorders

Altered thyroid and liver function tests

May cause insomnia or depression

None reported

No information available to require special precautions

Progestins may predispose the patient to gingival bleeding

Follow dosage schedule and do not take more than prescribed. You may experience sensitivity to sunlight (use sunblock, wear protective clothing and eyewear, and avoid extensive exposure to direct sunlight); dizziness, anxiety, depression (use caution when driving or engaging in tasks that require alertness until response to drug is known); changes in appetite (maintain adequate hydration and diet - 2-3 L/day of fluids unless instructed to restrict fluid intake); decreased libido or increased body hair (reversible when drug is discontinued); hot flashes (cool clothes and environment may help). May cause discoloration of stool (green). Report swelling of face, lips, or mouth; absence or altered menses; abdominal pain; vaginal itching, irritation, or discharge; heat, warmth, redness, or swelling of extremities; or sudden onset change in vision. Pregnancy precautions: Inform prescriber if you are pregnant. Do not get pregnant during or for 1 month following therapy. Consult prescriber for instruction on appropriate barrier contraceptive measures. This drug may cause severe fetal defects.

Patients should receive a copy of the patient labeling for the drug

Injection, suspension: 100 mg/mL (5 mL); 150 mg/mL (1 mL); 400 mg/mL (1 mL, 2.5 mL, 10 mL)

Tablet: 2.5 mg, 5 mg, 10 mg